In addition, PD-1/PD-L1 axis inhibitors disrupt the interaction between PD-1 and PD-L1 and subsequently restore the immune response to tumor cells, ultimately improving survival outcomes for cancer patients (45). This evidence concerns the gene CD274 and neoplasm.